Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open Label, Multicenter Phase II Clinical Study in Rare Diseases to Evaluate Safety, Efficacy and PK of HLX208 for Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Next Previous
X
Search
Trial Profile

A Single-arm, Open Label, Multicenter Phase II Clinical Study in Rare Diseases to Evaluate Safety, Efficacy and PK of HLX208 for Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RX 208 (Primary)
  • Indications Erdheim-Chester disease; Langerhans cell histiocytosis
  • Focus Therapeutic Use
  • Sponsors Shanghai Henlius Biotech

    • Most Recent Events

    • 05 Dec 2023 According to a Shanghai Henlius Biotech media release, results from this trial were presented at the European Society for Medical Oncology Asia (ESMO Asia) Congress 2023.
    • 05 Dec 2023 Results presented in the Shanghai Henlius Biotech Media Release.
    • 07 Aug 2023 Planned End Date changed from 30 May 2024 to 30 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top